Abstract:Rationale: The molecular mechanisms underlying the pathogenesis of systemic insulin resistance in type 2 diabetes remain elusive. Growth hormone receptor (GHR) deficiency has long been known to improved insulin sensitivity. However, whether hepatic GHR overexpression or activation is a cause of insulin resistance is still unknown. The aim of this study was to identify the new role of GHR in systemic insulin resistance and explore the underlying mechanism. Method: Different samples obtained from obese humans, ob/ob mice, db/db mice, high-fat diet (HFD)-fed mice and primary mouse hepatocytes were used to evaluate the correlations between GHR and metabolic disorders. Recombinant adeno-associated viruses encoding GHR and STAT5 and GHR knockout mice were used to investigate the roles of hepatic GHR in glucose homeostasis. Tissue H&E, Oil Red O and PAS staining were performed for histomorphological analysis. Gel filtration chromatography was employed for the separation of serum RBP4-TTR complexes. Plasmids (related to GHR, STAT5 and HIF1α), siRNA oligos (siGHR and siSTAT5), luciferase activity and ChIP assays were used to explore the potential mechanism of hepatic GHR. Results: Here, we found that hepatic GHR expression was elevated during metabolic disorder. Accordingly, hepatic GHR overexpression disrupted systemic glucose homeostasis by promoting gluconeogenesis and disturbing insulin responsiveness in the liver. Meanwhile, hepatic GHR overexpression promoted lipolysis in white adipose tissue and repressed glucose utilization in skeletal muscle by promoting the circulating level of RBP4, which contributed to impaired systemic insulin action. A mechanistic study revealed that hepatic GHR disrupted systemic insulin sensitivity by increasing RBP4 transcription by activating STAT5. Additionally, overexpression of hepatic GHR promoted TTR transcriptional levels by enhancing the expression of HIF1α, which not only increased the protein stability of RBP4 but also inhibited renal clearance of RBP4 in serum. Conclusions: Hepatic GHR overexpression and activation accelerated systemic insulin resistance by increasing hepatic RBP4 production and maintaining circulating RBP4 homeostasis. Our current study provides novel insights into the pathogenesis of type 2 diabetes and its associated metabolic complications.

The insulin superfamily of growth-promoting proteins

The insulin-RB synapse in health and disease: cellular rocket science

Structure and Function of Insulin Receptor Family Proteins

Functional Significance of Type 1 Insulin-like Growth Factor-mediated Nuclear Translocation of the Insulin Receptor Substrate-1 and Β-Catenin

Insulin - like growth factor type 1 receptor and malignancy:An update

Insulin, insulin receptors, and cancer

Tumor suppressor and anti-inflammatory protein: an expanded view on insulin-degrading enzyme (IDE)

Activation of the insulin receptor by insulin-like growth factor 2

Antiproliferative MCR peptides block physical interaction of insulin with retinoblastoma protein (RB) in human lung cancer cells

Viral insulin-like peptides activate human insulin and IGF-1 receptor signaling: A paradigm shift for host-microbe interactions

Insulin-like Growth Factor I Receptor Signaling and Nuclear Translocation of Insulin Receptor Substrates 1 and 2.

Evolutionary Sequences and Structural Information-driven Reconstruction of New Insulin-like Growth Factor-I Peptide Variants

IRS proteins and the common path to diabetes

Radioimmunoassay of the Somatomedins/Insulin-like Growth Factors

Trans-omics analysis of insulin action reveals a cell growth subnetwork which co-regulates anabolic processes

Type I Insulin-Like Growth Factor Receptor and Tumor

Revisiting the IGF-1R as a breast cancer target

Identification of Insulin As a Novel Retinoic Acid Receptor‐related Orphan Receptor Α Target Gene

Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology.

Growth hormone receptor disrupts glucose homeostasis via promoting and stabilizing retinol binding protein 4

Insulin-like growth factor binding protein-related protein 1 and cancer.